Thomas, Susanna
Kabir, Masrura
Butcher, Belinda E.
Chou, Shaun
Mahajan, Hema
Farshid, Gelareh
Balleine, Rosemary
Pathmanathan, Nirmala http://orcid.org/0000-0001-9225-139X
Article History
Received: 21 December 2020
Accepted: 10 March 2021
First Online: 22 March 2021
Compliance with ethical standards
:
: ST declares employment at Australian Clinical Labs, Bella Vista, NSW 2153, Australia (July 2015 to present). BEB declares medical writing fees and statistical consulting fees paid to WriteSource Medical Pty Ltd for services provided to the following pharmaceutical companies: AbbVie, Actelion, Alexion, Bayer, BMS, Ferring, George Clinical, Hartmann, Janssen-Cilag Australia, Lilly, Lundbeck, Medlab, Merck, Novartis, Nucleus Network, Pfizer, Pharmaxis, Roche, Sandoz, Sanofi, UCB. SC declares remuneration from Tissue Pathology and Diagnostic Oncology, ICPMR, Pathology West. HM declares remuneration from the Institute of Clinical Pathology and Medical Research, Pathology West. GF declares remuneration has been received from SA Pathology, Royal Adelaide Hospital. RB declares employment at the Institute of Clinical Pathology and Medical Research, Pathology West, NSW Health Pathology, NSW 2145 (to October 2016) and the Children’s Medical Research Institute, Westmead NSW (October 2016 to present). NP declares remuneration from Douglass Hanly Moir Pathology. The remaining authors have no conflicts to declare.
: Ethics approval was obtained from Westmead Scientific Advisory QA Committee and the Secretary of the WSLHD Human Research Ethics Committee. Reference number: 1812–10 QA.
: This project was approved as a quality assurance project. Consent was not required as data were collected retrospectively, and data were de-identified prior to analysis.
: Not applicable.